ID   MKNK2_HUMAN             Reviewed;         465 AA.
AC   Q9HBH9; Q6GPI3; Q9HBH8; Q9UHR0; Q9Y2N6;
DT   30-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   05-OCT-2010, entry version 101.
DE   RecName: Full=MAP kinase-interacting serine/threonine-protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=MAP kinase signal-integrating kinase 2;
DE            Short=Mnk2;
GN   Name=MKNK2; Synonyms=GPRK7, MNK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5), TISSUE
RP   SPECIFICITY, AND INTERACTION WITH ESR2.
RC   TISSUE=Fetal brain;
RX   MEDLINE=20469405; PubMed=11013076; DOI=10.1006/geno.2000.6299;
RA   Slentz-Kesler K., Moore J.T., Lombard M., Zhang J., Hollingsworth R.,
RA   Weiner M.P.;
RT   "Identification of the human Mnk2 gene (MKNK2) through protein
RT   interaction with estrogen receptor beta.";
RL   Genomics 69:63-71(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Adrenal gland;
RA   Li Y., Shi J., Huang C., Ren S., Fu S., Zhou J., Yu Y., Xu S.,
RA   Wang Y., Fu G., Chen Z., Han Z.;
RT   "A novel gene expressed in human adrenal gland.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, PHOSPHORYLATION AT THR-244; THR-249 AND THR-379, AND
RP   MUTAGENESIS OF THR-244; THR-249 AND THR-379.
RC   TISSUE=Leukocyte;
RX   MEDLINE=21356974; PubMed=11463832;
RX   DOI=10.1128/MCB.21.16.5500-5511.2001;
RA   Knauf U., Tschopp C., Gram H.;
RT   "Negative regulation of protein translation by mitogen-activated
RT   protein kinase-interacting kinases 1 and 2.";
RL   Mol. Cell. Biol. 21:5500-5511(2001).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 72-385 IN COMPLEX WITH ZINC,
RP   AND SUBUNIT.
RX   PubMed=16216586; DOI=10.1016/j.str.2005.07.013;
RA   Jauch R., Jaekel S., Netter C., Schreiter K., Aicher B., Jaeckle H.,
RA   Wahl M.C.;
RT   "Crystal structures of the Mnk2 kinase domain reveal an inhibitory
RT   conformation and a zinc binding site.";
RL   Structure 13:1559-1568(2005).
RN   [9]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-73.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: May play a role in the response to environmental stress
CC       and cytokines. Appears to regulate transcription by
CC       phosphorylating EIF4E, thus increasing the affinity of this
CC       protein for the 7-methylguanosine-containing mRNA cap.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- SUBUNIT: Monomer. Interacts with the C-terminal regions of EIF4G1
CC       and EIF4G2. Also binds to dephosphorylated ERK1 and ERK2. Isoform
CC       2 interacts with ESR2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=2a;
CC         IsoId=Q9HBH9-1; Sequence=Displayed;
CC       Name=2; Synonyms=2b;
CC         IsoId=Q9HBH9-2; Sequence=VSP_007353, VSP_007354;
CC       Name=3;
CC         IsoId=Q9HBH9-3; Sequence=Not described;
CC       Name=4;
CC         IsoId=Q9HBH9-4; Sequence=Not described;
CC       Name=5;
CC         IsoId=Q9HBH9-5; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed in all tissues
CC       examined. Isoform 2 is expressed at higher levels in the ovary
CC       than is isoform 1.
CC   -!- PTM: Dual phosphorylation of Thr-244 and Thr-249 activates the
CC       kinase. Phosphorylation of Thr-379 activates the kinase.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF237775; AAG26336.1; -; mRNA.
DR   EMBL; AF237776; AAG26337.1; -; mRNA.
DR   EMBL; AF125532; AAF17226.1; -; mRNA.
DR   EMBL; BC073140; AAH73140.1; -; mRNA.
DR   IPI; IPI00396114; -.
DR   IPI; IPI00479444; -.
DR   RefSeq; NP_060042.2; -.
DR   RefSeq; NP_951009.1; -.
DR   UniGene; Hs.515032; -.
DR   PDB; 2AC3; X-ray; 2.10 A; A=72-385.
DR   PDB; 2AC5; X-ray; 3.20 A; A=72-385.
DR   PDB; 2HW7; X-ray; 2.71 A; A=72-385.
DR   PDBsum; 2AC3; -.
DR   PDBsum; 2AC5; -.
DR   PDBsum; 2HW7; -.
DR   ProteinModelPortal; Q9HBH9; -.
DR   SMR; Q9HBH9; 71-369, 83-398.
DR   IntAct; Q9HBH9; 1.
DR   STRING; Q9HBH9; -.
DR   PhosphoSite; Q9HBH9; -.
DR   PRIDE; Q9HBH9; -.
DR   Ensembl; ENST00000250896; ENSP00000250896; ENSG00000099875.
DR   GeneID; 2872; -.
DR   KEGG; hsa:2872; -.
DR   UCSC; uc002lus.2; human.
DR   CTD; 2872; -.
DR   GeneCards; GC19M001988; -.
DR   HGNC; HGNC:7111; MKNK2.
DR   HPA; HPA021875; -.
DR   MIM; 605069; gene.
DR   PharmGKB; PA30830; -.
DR   HOVERGEN; HBG106949; -.
DR   InParanoid; Q9HBH9; -.
DR   OMA; VQKKTAE; -.
DR   OrthoDB; EOG9GF60B; -.
DR   PhylomeDB; Q9HBH9; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 11333; -.
DR   ArrayExpress; Q9HBH9; -.
DR   Bgee; Q9HBH9; -.
DR   CleanEx; HS_MKNK2; -.
DR   Genevestigator; Q9HBH9; -.
DR   GermOnline; ENSG00000099875; Homo sapiens.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor linked signaling pathway; TAS:ProtInc.
DR   GO; GO:0007243; P:intracellular protein kinase cascade; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0006950; P:response to stress; IEA:InterPro.
DR   InterPro; IPR020636; Ca/CaM-dep_prot_kinase-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR015731; MAP_Kinase_interacting_Kinase.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   PANTHER; PTHR22982; Ca/CaM-dep_prot_kinase-like; 1.
DR   PANTHER; PTHR22982:SF21; MAP_k_interact_k; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Kinase; Magnesium; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Serine/threonine-protein kinase; Transferase;
KW   Translation regulation; Zinc.
FT   CHAIN         1    465       MAP kinase-interacting serine/threonine-
FT                                protein kinase 2.
FT                                /FTId=PRO_0000086336.
FT   DOMAIN       84    388       Protein kinase.
FT   NP_BIND      90     98       ATP (By similarity).
FT   ACT_SITE    205    205       Proton acceptor (By similarity).
FT   METAL       299    299       Zinc.
FT   METAL       311    311       Zinc.
FT   METAL       314    314       Zinc.
FT   BINDING     113    113       ATP (By similarity).
FT   MOD_RES     244    244       Phosphothreonine.
FT   MOD_RES     249    249       Phosphothreonine.
FT   MOD_RES     379    379       Phosphothreonine.
FT   MOD_RES     452    452       Phosphoserine.
FT   VAR_SEQ     386    414       NSCAKDLTSFAAEAIAMNRQLAQHDEDLA -> WDSHFLLP
FT                                PHPCRIHVRPGGLVRTVTVNE (in isoform 2).
FT                                /FTId=VSP_007353.
FT   VAR_SEQ     415    465       Missing (in isoform 2).
FT                                /FTId=VSP_007354.
FT   VARIANT      10     10       Q -> K (in dbSNP:rs3746101).
FT                                /FTId=VAR_051648.
FT   VARIANT      73     73       D -> N (in dbSNP:rs56158214).
FT                                /FTId=VAR_040805.
FT   VARIANT     428    428       R -> Q (in dbSNP:rs34475638).
FT                                /FTId=VAR_051649.
FT   MUTAGEN     244    244       T->A: Loss of kinase activity; when
FT                                associated with T-249.
FT   MUTAGEN     249    249       T->A: Loss of kinase activity; when
FT                                associated with T-244.
FT   MUTAGEN     379    379       T->D: Constitutively active.
FT   CONFLICT    261    261       V -> L (in Ref. 2; AAF17226).
FT   TURN         79     81
FT   STRAND       94    102
FT   STRAND      104    106
FT   STRAND      109    116
FT   HELIX       123    135
FT   STRAND      145    151
FT   STRAND      154    160
FT   HELIX       167    174
FT   HELIX       179    198
FT   HELIX       208    210
FT   STRAND      211    214
FT   STRAND      216    219
FT   STRAND      221    224
FT   HELIX       254    256
FT   HELIX       259    264
FT   HELIX       267    272
FT   HELIX       273    275
FT   HELIX       276    290
FT   HELIX       312    324
FT   HELIX       331    334
FT   HELIX       339    348
FT   TURN        353    355
FT   HELIX       359    364
SQ   SEQUENCE   465 AA;  51875 MW;  D6D4BE6C541012B1 CRC64;
     MVQKKPAELQ GFHRSFKGQN PFELAFSLDQ PDHGDSDFGL QCSARPDMPA SQPIDIPDAK
     KRGKKKKRGR ATDSFSGRFE DVYQLQEDVL GEGAHARVQT CINLITSQEY AVKIIEKQPG
     HIRSRVFREV EMLYQCQGHR NVLELIEFFE EEDRFYLVFE KMRGGSILSH IHKRRHFNEL
     EASVVVQDVA SALDFLHNKG IAHRDLKPEN ILCEHPNQVS PVKICDFDLG SGIKLNGDCS
     PISTPELLTP CGSAEYMAPE VVEAFSEEAS IYDKRCDLWS LGVILYILLS GYPPFVGRCG
     SDCGWDRGEA CPACQNMLFE SIQEGKYEFP DKDWAHISCA AKDLISKLLV RDAKQRLSAA
     QVLQHPWVQG CAPENTLPTP MVLQRNSCAK DLTSFAAEAI AMNRQLAQHD EDLAEEEAAG
     QGQPVLVRAT SRCLQLSPPS QSKLAQRRQR ASLSSAPVVL VGDHA
//
